ARTICLE | Emerging Company Profile
InterVenn: liquid biopsy diagnostics based on glycoproteins
InterVenn builds on research by scientific founders Bertozzi, Lebrillo to develop glycoproteomic cancer diagnostics
November 18, 2020 2:06 AM UTC
InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.
The company announced Monday that it raised a $34 million series B round led by Anzu Partners and hired John Leite, former VP of clinical BD at Illumina Inc. (NASDAQ:ILMN), as CBO. The news comes as the company is preparing to launch its first diagnostic — a liquid biopsy ovarian cancer test — next half. ...
BCIQ Company Profiles